Concepedia
Statistics
Publications
74
Citations
9.7K
H-Index
47
Active since
1984
Affiliations
University of Virginia(Current)
Eli Lilly (United States)
University of Virginia Health System
Indiana University – Purdue University Indianapolis
Virginia Commonwealth University
Mark L. Hartman is an author at University of Virginia specializing in endocrinology, growth hormone, and medicine.
Publications per year
1984–2025
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Ania M. Jastreboff, Lee M. Kaplan, Juan P. Frías et al. · New England Journal of Medicine · 2023 · 966 citations
Pharmacy, Pharmacology, Pharmacotherapy +17
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
Rohit Loomba, Mark L. Hartman, Eric Lawitz et al. · New England Journal of Medicine · 2024 · 783 citations
Medicine, Pharmacology, Pharmacotherapy +17
Sensitivity and Specificity of Six Tests for the Diagnosis of Adult GH Deficiency
Beverly M. K. Biller, Mary H. Samuels, Anthony J. Zagar et al. · The Journal of Clinical Endocrinology & Metabolism · 2002 · 405 citations · Full text
Medicine, Endocrinology, Comparative Endocrinology +16
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Julio Rosenstock, Juan P. Frías, Ania M. Jastreboff et al. · The Lancet · 2023 · 376 citations
Medicine, Endocrinology, Pharmacology +14
Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
Mark L. Hartman, Arun J. Sanyal, Rohit Loomba et al. · Diabetes Care · 2020 · 345 citations · Full text
Medicine, Endocrinology, Pharmacology +17
1–5 of 74